EDEN PRAIRIE, Minn., Oct. 23 /PRNewswire/ -- Celleration, Inc. announced the publication of the results of an important clinical study Evaluation of the Effectiveness of MIST Ultrasound Therapy for the Healing of Chronic Wounds. The study was conducted in a tertiary-referral hospital-based wound clinic. Overall, 69% of the wounds in the study were healed using an intent- to-treat model. When low-frequency, non-contact ultrasound (MIST Therapy(R)) was used as a stand-alone device; median time to healing was 7 weeks. Historic controls were healed with a median time to healing of 10 weeks; however, a statistically significant number of these patients required wound-related hospitalization and surgical procedures to achieve closure compared with the wounds in the present study. These new findings were published by William J. Ennis, DO, Medical Director of the Wound Treatment Program, St. James Olympia Fields Hospital, Olympia Fields, IL the lead investigator in the study in the October 2006 issue of the peer reviewed journal Advances in Skin & Wound Care.
“We are very excited about the results of this study,” commented Kevin Nickels, CEO. “This is the second clinical study published adding to the growing body of evidence for MIST Therapy. Celleration, Inc. is committed to the ongoing development and execution of high quality research to continually broaden the clinical use of MIST Technology(TM); and to provide our customers and the health care professionals well designed scientific studies on which to make evidence based treatment decisions.”
Celleration’s proprietary non-contact MIST Technology can be used on a variety of wounds including, acute, traumatic, chronic and dehisced wounds to promote wound healing. MIST Therapy is a bioactive therapy that promotes healing through cell stimulation while removing bacteria. It is an advanced modality for modern wound care, a painless ultrasound device. The use of MIST Therapy is an attractive technology for health care professionals since its use affects multiple aspects of a chronic wound to promote healing. The treatment takes only minutes; it is easy to use, compact and portable, and comfortable for patients with painful wounds.
About the Company:
Celleration, Inc. a privately held medical device company was founded in 1999, to develop and commercialize its therapeutic ultrasound platform. The patented MIST Technology utilizes low intensity ultrasonic sound waves to produce an energized mist of sterile saline in a non-contact fashion. Critical to the Company’s strategy is ongoing clinical and scientific research to provide evidence supporting the efficacy of this new technology.
For more information on Celleration, Inc. and the MIST Therapy System contact Mr. Chris Ernster, VP of Sales and Marketing 952-224-8700.
Celleration, Inc.
CONTACT: Kevin Nickels, President and CEO of Celleration, Inc.,+1-952-224-8700
Web site: http://www.celleration.com/
